Dynamics of lung function in children treated with salmeterol/ fluticasone propionate combination (SFC)

E. G. Kondiourina, T. N. Elkina, L. V. Stepanova, O. A. Gribanova, N. F. Zhoukova (Novosibirsk, Russia)

Source: Annual Congress 2003 - Lung function tests in childhood asthma
Session: Lung function tests in childhood asthma
Session type: Thematic Poster Session
Number: 3119
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. G. Kondiourina, T. N. Elkina, L. V. Stepanova, O. A. Gribanova, N. F. Zhoukova (Novosibirsk, Russia). Dynamics of lung function in children treated with salmeterol/ fluticasone propionate combination (SFC). Eur Respir J 2003; 22: Suppl. 45, 3119

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 292s
Year: 2005

Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010


Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Comparison of fluticasone propionate plus theophylline with the salmeterol/fluticasone propionate combination in Japanese asthmatics
Source: Eur Respir J 2005; 26: Suppl. 49, 44s
Year: 2005

Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

The safety of double dose salmeterol/fluticasone proprionate (SFC) in adult asthmatics
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Comparison of salmeterol/fluticasone propionate (sal/fp) combination versus monotherapy with fluticasone propionate (fp) in patients with mild to moderate asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

Comparison of inhaled ciclesonide, fluticasone propinate and fluticasone propionate + salmeterol in maintaining asthma control
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009

Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Efficacy of salmeterol/fluticasone propionate MDI versus higher dose fluticasone propionate in adolescent and adult asthmatics uncontrolled on fluticasone propionate alone
Source: Eur Respir J 2003; 22: Suppl. 45, 438s
Year: 2003

Variability in asthma and treatment efficacy as determined by weekly response rates with fluticasone propionate/salmeterol 100/50mcg (FSC) compared with montelukast 10mg (MON)
Source: Eur Respir J 2003; 22: Suppl. 45, 259s
Year: 2003

Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone
Source: International Congress 2017 – Asthma management
Year: 2017


Superiority of the ‘triple‘ therapy of salmeterol/fluticasone propionate (SFC) and tiotropium (TIO) vs. individual components in COPD
Source: Annual Congress 2007 - New drugs for COPD
Year: 2007



Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management
Source: Eur Respir J 2002; 20: Suppl. 38, 388s
Year: 2002

EXCEL: regular maintenance therapy with salmeterol/fluticasone propionate combination (SFC) reduces exacerbations more effectively than with formoterol/budesonide combination (FBC)
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Synergy with salmeterol and fluticasone propionate after administration from a single inhaler (Seretide™)
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

The effects of fluticasone propionate/salmeterole 50/100 μg bid in children with asthma versus beclometasone propionate 200 μg BD and fluticasone propionate 100 μg bid dry powder inhaletors
Source: Eur Respir J 2004; 24: Suppl. 48, 378s
Year: 2004

Efficacy and safety of fluticasone propionate/salmeterol DISKUS and fluticasone propionate DISKUS and HFA in children
Source: Eur Respir J 2005; 26: Suppl. 49, 161s
Year: 2005